Sagimet Biosciences Inc.

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors. These inhibitors are designed to target dysfunctional metabolic and fibrotic pathways implicated in diseases stemming from the overproduction of the fatty acid palmitate. The company's headquarters are located in San Mateo, California.

The company's lead product candidate is denifanstat (formerly TVB-2640), an oral, once-daily, selective FASN inhibitor. Denifanstat is currently in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH, previously known as NASH), moderate to severe acne, and certain FASN-dependent tumor types. Sagimet's pipeline also includes TVB-3567, another FASN inhibitor, which is being developed for acne and solid tumors.

In recent developments, Sagimet Biosciences successfully completed a Phase 2b clinical trial (FASCINATE-2) for denifanstat in MASH patients. The company's partner, Ascletis, also reported statistically significant results from a Phase 3 clinical trial of denifanstat for moderate to severe acne in China. Building on this, Sagimet plans to initiate a registrational Phase 3 trial for denifanstat in moderate to severe acne in the United States in the second half of 2026. The company recently raised $175 million through an underwritten offering to support these clinical advancements. David Happel serves as the Chief Executive Officer, appointed in October 2022, and Andreas Grauer was appointed Chief Medical Officer in April 2026.